75. Heine, A., Held, S.A., Bringmann, A., Holderried, T.A., and Brossart, P. (2011). Immunomodulatory effects of anti-angiogenic drugs. Leukemia 25, 899-905. 10.1038/leu.2011.24.

76. Stehle, F., Schulz, K., Fahldieck, C., Kalich, J., Lichtenfels, R., Riemann, D., and Seliger, B. (2013). Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem 288, 16334-16347. 10.1074/jbc.M112.437962.

77. Prasanna, P.G., Citrin, D.E., Hildesheim, J., Ahmed, M.M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., Deursen, J.V., Goronzy, J., et al. (2021). Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. J Natl Cancer Inst 113, 1285-1298. 10.1093/jnci/djab064.

78. Wang, L., Lankhorst, L., and Bernards, R. (2022). Exploiting senescence for the treatment of cancer. Nat Rev Cancer 22, 340-355. 10.1038/s41568-022-00450-9.

79. Zhang, L., Pitcher, L.E., Prahalad, V., Niedernhofer, L.J., and Robbins, P.D. (2023). Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J 290, 1362-1383. 10.1111/febs.16350.

80. Wang, B., and Demaria, M. (2021). The Quest to Define and Target Cellular Senescence in Cancer. Cancer Res 81, 6087-6089. 10.1158/0008-5472.CAN-21-2032.

81. Lee, S., and Schmitt, C.A. (2019). The dynamic nature of senescence in cancer. Nat Cell Biol 21, 94-101. 10.1038/s41556-018-0249-2.

82. Chakradeo, S., Elmore, L.W., and Gewirtz, D.A. (2016). Is Senescence Reversible? Curr Drug Targets 17, 460-466.

83. Romaniello, D., Gelfo, V., Pagano, F., Ferlizza, E., Sgarzi, M., Mazzeschi, M., Morselli, A., Miano, C., D'Uva, G., and Lauriola, M. (2022). Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization. Cell Mol Biol Lett 27, 20. 10.1186/s11658-022-00319-7.

84. Salunkhe, S., Mishra, S.V., Nair, J., Shah, S., Gardi, N., Thorat, R., Sarkar, D., Rajendra, J., Kaur, E., and Dutt, S. (2021). Nuclear localization of p65 reverses therapy-induced senescence. J Cell Sci 134. 10.1242/jcs.253203.

85. Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C.B., Roberto, M.P., Tovar, V., Sia, D., Molina-Sanchez, P., Nguyen, C.B., et al. (2017). Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut 66, 1286-1296. 10.1136/gutjnl-2016-312268.

86. Maskey, R.S., Wang, F., Lehman, E., Wang, Y., Emmanuel, N., Zhong, W., Jin, G., Abraham, R.T., Arndt, K.T., Myers, J.S., and Mazurek, A. (2021). Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells. Cell Cycle 20, 65-80. 10.1080/15384101.2020.1859195.

87. Fleury, H., Malaquin, N., Tu, V., Gilbert, S., Martinez, A., Olivier, M.A., Sauriol, A., Communal, L., Leclerc-Desaulniers, K., Carmona, E., et al. (2019). Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat Commun 10, 2556. 10.1038/s41467-019-10460-1.

88. Madorsky Rowdo, F.P., Baron, A., von Euw, E.M., and Mordoh, J. (2017). In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. Oncol Rep 37, 1367-1378. 10.3892/or.2017.5363.

89. Kurppa, K.J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E.H., Xie, Y., Lim, K., Cejas, P., et al. (2020). Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell 37, 104-122 e112. 10.1016/j.ccell.2019.12.006.

90. Hu, Z., Yuan, J., Long, M., Jiang, J., Zhang, Y., Zhang, T., Xu, M., Fan, Y., Tanyi, J.L., Montone, K.T., et al. (2021). The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer 2, 1406-1422. 10.1038/s43018-021-00282-w.
75. Heine, A., Held, S.A., Bringmann, A., Holderried, T.A., and Brossart, P. (2011). Immunomodulatory effects of anti-angiogenic drugs. Leukemia 25, 899-905. 10.1038/leu.2011.24.

76. Stehle, F., Schulz, K., Fahldieck, C., Kalich, J., Lichtenfels, R., Riemann, D., and Seliger, B. (2013). Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem 288, 16334-16347. 10.1074/jbc.M112.437962.

77. Prasanna, P.G., Citrin, D.E., Hildesheim, J., Ahmed, M.M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., Deursen, J.V., Goronzy, J., et al. (2021). Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. J Natl Cancer Inst 113, 1285-1298. 10.1093/jnci/djab064.

78. Wang, L., Lankhorst, L., and Bernards, R. (2022). Exploiting senescence for the treatment of cancer. Nat Rev Cancer 22, 340-355. 10.1038/s41568-022-00450-9.

79. Zhang, L., Pitcher, L.E., Prahalad, V., Niedernhofer, L.J., and Robbins, P.D. (2023). Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J 290, 1362-1383. 10.1111/febs.16350.

80. Wang, B., and Demaria, M. (2021). The Quest to Define and Target Cellular Senescence in Cancer. Cancer Res 81, 6087-6089. 10.1158/0008-5472.CAN-21-2032.

81. Lee, S., and Schmitt, C.A. (2019). The dynamic nature of senescence in cancer. Nat Cell Biol 21, 94-101. 10.1038/s41556-018-0249-2.

82. Chakradeo, S., Elmore, L.W., and Gewirtz, D.A. (2016). Is Senescence Reversible? Curr Drug Targets 17, 460-466.

83. Romaniello, D., Gelfo, V., Pagano, F., Ferlizza, E., Sgarzi, M., Mazzeschi, M., Morselli, A., Miano, C., D'Uva, G., and Lauriola, M. (2022). Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization. Cell Mol Biol Lett 27, 20. 10.1186/s11658-022-00319-7.

84. Salunkhe, S., Mishra, S.V., Nair, J., Shah, S., Gardi, N., Thorat, R., Sarkar, D., Rajendra, J., Kaur, E., and Dutt, S. (2021). Nuclear localization of p65 reverses therapy-induced senescence. J Cell Sci 134. 10.1242/jcs.253203.

85. Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C.B., Roberto, M.P., Tovar, V., Sia, D., Molina-Sanchez, P., Nguyen, C.B., et al. (2017). Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut 66, 1286-1296. 10.1136/gutjnl-2016-312268.

86. Maskey, R.S., Wang, F., Lehman, E., Wang, Y., Emmanuel, N., Zhong, W., Jin, G., Abraham, R.T., Arndt, K.T., Myers, J.S., and Mazurek, A. (2021). Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells. Cell Cycle 20, 65-80. 10.1080/15384101.2020.1859195.

87. Fleury, H., Malaquin, N., Tu, V., Gilbert, S., Martinez, A., Olivier, M.A., Sauriol, A., Communal, L., Leclerc-Desaulniers, K., Carmona, E., et al. (2019). Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat Commun 10, 2556. 10.1038/s41467-019-10460-1.

88. Madorsky Rowdo, F.P., Baron, A., von Euw, E.M., and Mordoh, J. (2017). In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. Oncol Rep 37, 1367-1378. 10.3892/or.2017.5363.

89. Kurppa, K.J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E.H., Xie, Y., Lim, K., Cejas, P., et al. (2020). Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell 37, 104-122 e112. 10.1016/j.ccell.2019.12.006.

90. Hu, Z., Yuan, J., Long, M., Jiang, J., Zhang, Y., Zhang, T., Xu, M., Fan, Y., Tanyi, J.L., Montone, K.T., et al. (2021). The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer 2, 1406-1422. 10.1038/s43018-021-00282-w.
91. Saleh, T., Tyutyunyk-Massey, L., Murray, G.F., Alotaibi, M.R., Kawale, A.S., Elsayed, Z., Henderson, S.C., Yakovlev, V., Elmore, L.W., Toor, A., et al. (2019). Tumor cell escape from therapy-induced senescence. *Biochem Pharmacol* **162**, 202-212. 10.1016/j.bcp.2018.12.013.

92. Hao, X., Zhao, B., Zhou, W., Liu, H., Fukumoto, T., Gabrilovich, D., and Zhang, R. (2021). Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. *iScience* **24**, 102016. 10.1016/j.isci.2020.102016.

93. Paffenholz, S.V., Salvagno, C., Ho, Y.J., Limjoco, M., Baslan, T., Tian, S., Kulick, A., de Stanchina, E., Wilkinson, J.E., Barriga, F.M., et al. (2022). Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proc Natl Acad Sci U S A **119**. 10.1073/pnas.2117754119.

94. Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A.K., Kothari, A., Wang, D., Visal, T., Li, M.K., Pinto, J., Castrillon, J.A., et al. (2019). PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov **9**, 722-737. 10.1158/2159-8290.CD-18-1218.

95. Jing, W., McAllister, D., Vonderhaar, E.P., Palen, K., Riese, M.J., Gershan, J., Johnson, B.D., and Dwinell, M.B. (2019). STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. J Immunother Cancer **7**, 115. 10.1186/s40425-019-0573-5.

96. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., Vitale, I., Goubar, A., Baracco, E.E., Remedios, C., et al. (2014). Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med **20**, 1301-1309. 10.1038/nm.3708.

97. Adachi, Y., Kamiyama, H., Ichikawa, K., Fukushima, S., Ozawa, Y., Yamaguchi, S., Goda, S., Kimura, T., Kodama, K., Matsuki, M., et al. (2022). Inhibition of FGFR Reactivates IFNgamma Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. Cancer Res **82**, 292-306. 10.1158/0008-5472.CAN-20-2426.

98. Goel, S., DeCristo, M.J., Watt, A.C., BrinJones, H., Sceneay, J., Li, B.B., Khan, N., Ubellacker, J.M., Xie, S., Metzger-Filho, O., et al. (2017). CDK4/6 inhibition triggers anti-tumour immunity. Nature **548**, 471-475. 10.1038/nature23465.

99. Yang, H., Lee, W.S., Kong, S.J., Kim, C.G., Kim, J.H., Chang, S.K., Kim, S., Kim, G., Chon, H.J., and Kim, C. (2019). STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest **129**, 4350-4364. 10.1172/JCI125413.

100. Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., and et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A **92**, 9363-9367. 10.1073/pnas.92.20.9363.

101. Kurz, D.J., Decary, S., Hong, Y., and Erusalimsky, J.D. (2000). Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci **113** (*Pt 20*), 3613-3622. 10.1242/jcs.113.20.3613.

102. Lee, B.Y., Han, J.A., Im, J.S., Morrone, A., Johung, K., Goodwin, E.C., Kleijer, W.J., DiMaio, D., and Hwang, E.S. (2006). Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell **5**, 187-195. 10.1111/j.1474-9726.2006.00199.x.

103. Ruzickova, E., Skoupa, N., Dolezel, P., Smith, D.A., and Mlejnek, P. (2019). The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance. Biomolecules **9**, 10.3390/biom9110675.

104. Gotink, K.J., Broxterman, H.J., Labots, M., de Haas, R.R., Dekker, H., Honeywell, R.J., Rudek, M.A., Beerepoot, L.V., Musters, R.J., Jansen, G., et al. (2011). Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res **17**, 7337-7346. 10.1158/1078-0432.CCR-11-1667.

105. Fassl, A., Brain, C., Abu-Remaileh, M., Stukan, I., Butter, D., Stepien, P., Feit, A.S., Bergholz, J., Michowski, W., Otto, T., et al. (2020). Increased lysosomal biomass is responsible for the
91. Saleh, T., Tyutyunyk-Massey, L., Murray, G.F., Alotaibi, M.R., Kawale, A.S., Elsayed, Z., Henderson, S.C., Yakovlev, V., Elmore, L.W., Toor, A., et al. (2019). Tumor cell escape from therapy-induced senescence. *Biochem Pharmacol* **162**, 202-212. 10.1016/j.bcp.2018.12.013.

92. Hao, X., Zhao, B., Zhou, W., Liu, H., Fukumoto, T., Gabrilovich, D., and Zhang, R. (2021). Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. *iScience* **24**, 102016. 10.1016/j.isci.2020.102016.

93. Paffenholz, S.V., Salvagno, C., Ho, Y.J., Limjoco, M., Baslan, T., Tian, S., Kulick, A., de Stanchina, E., Wilkinson, J.E., Barriga, F.M., et al. (2022). Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proc Natl Acad Sci U S A **119**. 10.1073/pnas.2117754119.

94. Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A.K., Kothari, A., Wang, D., Visal, T., Li, M.K., Pinto, J., Castrillon, J.A., et al. (2019). PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov **9**, 722-737. 10.1158/2159-8290.CD-18-1218.

95. Jing, W., McAllister, D., Vonderhaar, E.P., Palen, K., Riese, M.J., Gershan, J., Johnson, B.D., and Dwinell, M.B. (2019). STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. J Immunother Cancer **7**, 115. 10.1186/s40425-019-0573-5.

96. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., Vitale, I., Goubar, A., Baracco, E.E., Remedios, C., et al. (2014). Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med **20**, 1301-1309. 10.1038/nm.3708.

97. Adachi, Y., Kamiyama, H., Ichikawa, K., Fukushima, S., Ozawa, Y., Yamaguchi, S., Goda, S., Kimura, T., Kodama, K., Matsuki, M., et al. (2022). Inhibition of FGFR Reactivates IFNgamma Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. Cancer Res **82**, 292-306. 10.1158/0008-5472.CAN-20-2426.

98. Goel, S., DeCristo, M.J., Watt, A.C., BrinJones, H., Sceneay, J., Li, B.B., Khan, N., Ubellacker, J.M., Xie, S., Metzger-Filho, O., et al. (2017). CDK4/6 inhibition triggers anti-tumour immunity. Nature **548**, 471-475. 10.1038/nature23465.

99. Yang, H., Lee, W.S., Kong, S.J., Kim, C.G., Kim, J.H., Chang, S.K., Kim, S., Kim, G., Chon, H.J., and Kim, C. (2019). STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest **129**, 4350-4364. 10.1172/JCI125413.

100. Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., and et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A **92**, 9363-9367. 10.1073/pnas.92.20.9363.

101. Kurz, D.J., Decary, S., Hong, Y., and Erusalimsky, J.D. (2000). Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci **113** (*Pt 20*), 3613-3622. 10.1242/jcs.113.20.3613.

102. Lee, B.Y., Han, J.A., Im, J.S., Morrone, A., Johung, K., Goodwin, E.C., Kleijer, W.J., DiMaio, D., and Hwang, E.S. (2006). Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell **5**, 187-195. 10.1111/j.1474-9726.2006.00199.x.

103. Ruzickova, E., Skoupa, N., Dolezel, P., Smith, D.A., and Mlejnek, P. (2019). The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance. Biomolecules **9**, 10.3390/biom9110675.

104. Gotink, K.J., Broxterman, H.J., Labots, M., de Haas, R.R., Dekker, H., Honeywell, R.J., Rudek, M.A., Beerepoot, L.V., Musters, R.J., Jansen, G., et al. (2011). Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res **17**, 7337-7346. 10.1158/1078-0432.CCR-11-1667.

105. Fassl, A., Brain, C., Abu-Remaileh, M., Stukan, I., Butter, D., Stepien, P., Feit, A.S., Bergholz, J., Michowski, W., Otto, T., et al. (2020). Increased lysosomal biomass is responsible for the
resistance of triple-negative breast cancers to CDK4/6 inhibition. *Sci Adv* 6, eabb2210. 10.1126/sciadv.abb2210.

106. Colombo, F., Trombetta, E., Cetrangolo, P., Maggioni, M., Razini, P., De Santis, F., Torrente, Y., Prati, D., Torresani, E., and Porretti, L. (2014). Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells. *PLoS One* 9, e114787. 10.1371/journal.pone.0114787.

107. Zhang, H., Zoued, A., Liu, X., Sit, B., and Waldor, M.K. (2020). Type I interferon remodels lysosome function and modifies intestinal epithelial defense. *Proc Natl Acad Sci U S A* 117, 29862-29871. 10.1073/pnas.2010723117.

108. Unterholzner, L., and Dunphy, G. (2019). cGAS-independent STING activation in response to DNA damage. *Mol Cell Oncol* 6, 1558682. 10.1080/23723556.2018.1558682.

109. Elgendy, M., Abdel-Aziz, A.K., Renne, S.L., Bornaghi, V., Procopio, G., Colecchia, M., Kanesvaran, R., Toh, C.K., Bossi, D., Pallavicini, I., et al. (2017). Dual modulation of MCL-1 and mTOR determines the response to sunitinib. *J Clin Invest* 127, 153-168. 10.1172/JCI84386.

110. Jimenez-Valerio, G., Martinez-Lozano, M., Bassani, N., Vidal, A., Ochoa-de-Olza, M., Suarez, C., Garcia-Del-Muro, X., Carles, J., Vinals, F., Graupera, M., et al. (2016). Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. *Cell Rep* 15, 1134-1143. 10.1016/j.celrep.2016.04.015.

111. Zhang, L., Wei, X., Wang, Z., Liu, P., Hou, Y., Xu, Y., Su, H., Koci, M.D., Yin, H., and Zhang, C. (2023). NF-kappaB activation enhances STING signaling by altering microtubule-mediated STING trafficking. *Cell Rep* 42, 112185. 10.1016/j.celrep.2023.112185.

112. Benci, J.L., Xu, B., Qiu, Y., Wu, T.J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D.S.M., Pauken, K.E., Huang, A.C., et al. (2016). Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. *Cell* 167, 1540-1554 e1512. 10.1016/j.cell.2016.11.022.

113. Shi, Y., Dolan, M., Mastri, M., Hill, J.W., Dommer, A., Benzekry, S., Eng, K., and Ebos, J.M.L. (2021). Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells. *bioRxiv*, 2021.2007.2001.450417. 10.1101/2021.07.01.450417.

114. Jacquelot, N., Yamazaki, T., Roberti, M.P., Duong, C.P.M., Andrews, M.C., Verlingue, L., Ferrere, G., Becharef, S., Vetizou, M., Daillere, R., et al. (2019). Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. *Cell Res* 29, 846-861. 10.1038/s41422-019-0224-x.

115. Dolan, M., Mastri, M., Tracz, A., Christensen, J.G., Chatta, G., and Ebos, J.M.L. (2019). Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. *PLoS One* 14, e0220101. 10.1371/journal.pone.0220101.

116. Ebos, J.M., Mastri, M., Lee, C.R., Tracz, A., Hudson, J.M., Attwood, K., Cruz-Munoz, W.R., Jedeszko, C., Burns, P., and Kerbel, R.S. (2014). Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. *EMBO Mol Med* 6, 1561-1576. 10.15252/emmm.201403989.

117. Ebos, J.M., Lee, C.R., Bogdanovic, E., Alami, J., Van Slyke, P., Francia, G., Xu, P., Mutsaers, A.J., Dumont, D.J., and Kerbel, R.S. (2008). Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. *Cancer Res* 68, 521-529. 10.1158/0008-5472.CAN-07-3217.

118. Tracz, A., Mastri, M., Lee, C.R., Pili, R., and Ebos, J.M. (2014). Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy. *J Vis Exp.* 10.3791/51485.

119. Mundra, P.A., and Rajapakse, J.C. (2016). Gene and sample selection using T-score with sample selection. *J Biomed Inform* 59, 31-41. 10.1016/j.jbi.2015.11.003.
resistance of triple-negative breast cancers to CDK4/6 inhibition. *Sci Adv* 6, eabb2210. 10.1126/sciadv.abb2210.

106. Colombo, F., Trombetta, E., Cetrangolo, P., Maggioni, M., Razini, P., De Santis, F., Torrente, Y., Prati, D., Torresani, E., and Porretti, L. (2014). Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells. *PLoS One* 9, e114787. 10.1371/journal.pone.0114787.

107. Zhang, H., Zoued, A., Liu, X., Sit, B., and Waldor, M.K. (2020). Type I interferon remodels lysosome function and modifies intestinal epithelial defense. *Proc Natl Acad Sci U S A* 117, 29862-29871. 10.1073/pnas.2010723117.

108. Unterholzner, L., and Dunphy, G. (2019). cGAS-independent STING activation in response to DNA damage. *Mol Cell Oncol* 6, 1558682. 10.1080/23723556.2018.1558682.

109. Elgendy, M., Abdel-Aziz, A.K., Renne, S.L., Bornaghi, V., Procopio, G., Colecchia, M., Kanesvaran, R., Toh, C.K., Bossi, D., Pallavicini, I., et al. (2017). Dual modulation of MCL-1 and mTOR determines the response to sunitinib. *J Clin Invest* 127, 153-168. 10.1172/JCI84386.

110. Jimenez-Valerio, G., Martinez-Lozano, M., Bassani, N., Vidal, A., Ochoa-de-Olza, M., Suarez, C., Garcia-Del-Muro, X., Carles, J., Vinals, F., Graupera, M., et al. (2016). Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. *Cell Rep* 15, 1134-1143. 10.1016/j.celrep.2016.04.015.

111. Zhang, L., Wei, X., Wang, Z., Liu, P., Hou, Y., Xu, Y., Su, H., Koci, M.D., Yin, H., and Zhang, C. (2023). NF-kappaB activation enhances STING signaling by altering microtubule-mediated STING trafficking. *Cell Rep* 42, 112185. 10.1016/j.celrep.2023.112185.

112. Benci, J.L., Xu, B., Qiu, Y., Wu, T.J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D.S.M., Pauken, K.E., Huang, A.C., et al. (2016). Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. *Cell* 167, 1540-1554 e1512. 10.1016/j.cell.2016.11.022.

113. Shi, Y., Dolan, M., Mastri, M., Hill, J.W., Dommer, A., Benzekry, S., Eng, K., and Ebos, J.M.L. (2021). Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells. *bioRxiv*, 2021.2007.2001.450417. 10.1101/2021.07.01.450417.

114. Jacquelot, N., Yamazaki, T., Roberti, M.P., Duong, C.P.M., Andrews, M.C., Verlingue, L., Ferrere, G., Becharef, S., Vetizou, M., Daillere, R., et al. (2019). Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. *Cell Res* 29, 846-861. 10.1038/s41422-019-0224-x.

115. Dolan, M., Mastri, M., Tracz, A., Christensen, J.G., Chatta, G., and Ebos, J.M.L. (2019). Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. *PLoS One* 14, e0220101. 10.1371/journal.pone.0220101.

116. Ebos, J.M., Mastri, M., Lee, C.R., Tracz, A., Hudson, J.M., Attwood, K., Cruz-Munoz, W.R., Jedeszko, C., Burns, P., and Kerbel, R.S. (2014). Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. *EMBO Mol Med* 6, 1561-1576. 10.15252/emmm.201403989.

117. Ebos, J.M., Lee, C.R., Bogdanovic, E., Alami, J., Van Slyke, P., Francia, G., Xu, P., Mutsaers, A.J., Dumont, D.J., and Kerbel, R.S. (2008). Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. *Cancer Res* 68, 521-529. 10.1158/0008-5472.CAN-07-3217.

118. Tracz, A., Mastri, M., Lee, C.R., Pili, R., and Ebos, J.M. (2014). Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy. *J Vis Exp.* 10.3791/51485.

119. Mundra, P.A., and Rajapakse, J.C. (2016). Gene and sample selection using T-score with sample selection. *J Biomed Inform* 59, 31-41. 10.1016/j.jbi.2015.11.003.
<figure><img src="image_2.png" /><figcaption>Figure 1</figcaption></figure>
<caption>Figure 1</caption>

<caption>D</caption>

<figure><img src="image_3.png" /><figcaption>C</figcaption></figure>

<figure><img src="image_4.png" /><figcaption>E</figcaption></figure>

<figure><img src="image_5.png" /></figure>

<figure><img src="image_6.png" /><figcaption>G</figcaption></figure>

<figure><img src="image_7.png" /><figcaption>F</figcaption></figure>

<figure><img src="image_8.png" /><figcaption>H</figcaption></figure>

<figure><img src="image_9.png" /><figcaption>I</figcaption></figure>

<figure><img src="image_10.png" /><figcaption>J</figcaption></figure>

<figure><img src="image_11.png" /><figcaption>K</figcaption></figure>

<figure><img src="image_12.png" /><figcaption>L</figcaption></figure>

<figure><img src="image_13.png" /><figcaption>M</figcaption></figure>

<figure><img src="image_14.png" /><figcaption>N</figcaption></figure>

<figure><img src="image_15.png" /></figure>
<figure><img src="image_3.png" /><figcaption>Figure 2</figcaption></figure>

<figure><img src="image_4.png" /></figure>

<figure><img src="image_5.png" /></figure>

<figure><img src="image_6.png" /></figure>

<figure><img src="image_7.png" /></figure>

<figure><img src="image_8.png" /></figure>

<figure><img src="image_9.png" /></figure>

<figure><img src="image_10.png" /></figure>

<figure><img src="image_11.png" /></figure>
<figure><img src="image_16.png" /><figcaption>Figure 2</figcaption></figure>

<figure><img src="image_17.png" /></figure>

<figure><img src="image_18.png" /></figure>

<figure><img src="image_19.png" /></figure>

<figure><img src="image_20.png" /></figure>

<figure><img src="image_21.png" /></figure>

<figure><img src="image_22.png" /></figure>

<figure><img src="image_23.png" /></figure>

<figure><img src="image_24.png" /></figure>
<figure><img src="image_12.png" /><figcaption>Figure 3</figcaption></figure>
<figure><img src="image_25.png" /><figcaption>Figure 3</figcaption></figure>
<figure><img src="image_13.png" /><figcaption>Figure 4</figcaption></figure>
<figure><img src="image_26.png" /><figcaption>Figure 4</figcaption></figure>
<caption>Figure 5</caption>

<figure><img src="image_14.png" /><figcaption>A</figcaption></figure>

<figure><img src="image_15.png" /></figure>

Mouse: BALB/c
Treatment (Tx): none

<figure><img src="image_16.png" /></figure>

Mouse: SCID
Tx: none

<figure><img src="image_17.png" /></figure>

Mouse: BALB/c
Tx: α-CD8 Ab

<figure><img src="image_18.png" /><figcaption>B</figcaption></figure>

Days post Implantation

<figure><img src="image_19.png" /><figcaption>D</figcaption></figure>

Log₂FC vs. P (gated CD8+ cells)
Norm. to 1e6 tumor cells

<figure><img src="image_20.png" /><figcaption>E</figcaption></figure>

<figure><img src="image_21.png" /><figcaption>F</figcaption></figure>

<figure><img src="image_22.png" /><figcaption>G</figcaption></figure>

Log₂FC vs. SM- (gated CD8+ cells)
Norm. to 1e6 tumor cells

<figure><img src="image_23.png" /><figcaption>H</figcaption></figure>

<figure><img src="image_24.png" /><figcaption>I</figcaption></figure>

<figure><img src="image_25.png" /><figcaption>J</figcaption></figure>

<figure><img src="image_26.png" /><figcaption>K</figcaption></figure>

<figure><img src="image_27.png" /></figure>

Immune-stimulatory
<figure><img src="image_27.png" /><figcaption>Figure 5</figcaption></figure>

<figure><img src="image_28.png" /></figure>

<figure><img src="image_29.png" /></figure>

Days post Implantation

<figure><img src="image_30.png" /></figure>

<figure><img src="image_31.png" /></figure>

<figure><img src="image_32.png" /></figure>

<figure><img src="image_33.png" /></figure>

<figure><img src="image_34.png" /></figure>
<figure><img src="image_28.png" /><figcaption>Figure 6</figcaption></figure>
<figure><img src="image_35.png" /><figcaption>Figure 6</figcaption></figure>
## Parsed Citations

1. Upadhaya, S., Neftelinov, S.T., Hodge, J., and Campbell, J. (2022). Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nat Rev Drug Discov. 10.1038/d41573-022-00030-4.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

2. Vafaei, S., Zekiy, A.O., Khanamir, R.A., Zaman, B.A., Ghayourvahdat, A., Azimizonuzi, H., and Zamani, M. (2022). Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int 22, 2. 10.1186/s12935-021-02407-8.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

3. Varayathu, H., Sarathy, V., Thomas, B.E., Mufti, S.S., and Naik, R. (2021). Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. Front Oncol 11, 559161. 10.3389/fonc.2021.559161.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

4. Kohli, J., Wang, B., Brandenburg, S.M., Basisty, N., Evangelou, K., Varela-Eirin, M., Campisi, J., Schilling, B., Gorgoulis, V., and Demaria, M. (2021). Algorithmic assessment of cellular senescence in experimental and clinical specimens. Nat Protoc 16, 2471-2498. 10.1038/s41596-021-00505-5.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

5. Gonzalez-Gualda, E., Baker, A.G., Fruk, L., and Munoz-Espin, D. (2021). A guide to assessing cellular senescence in vitro and in vivo. FEBS J 288, 56-80. 10.1111/febs.15570.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

6. Davan-Wetton, C.S.A., Pessolano, E., Perretti, M., and Montero-Melendez, T. (2021). Senescence under appraisal: hopes and challenges revisited. Cell Mol Life Sci 78, 3333-3354.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

### 10.1007/s00018-020-03746-x.

7. Mastri, M., Tracz, A., Lee, C.R., Dolan, M., Attwood, K., Christensen, J.G., Liu, S., and Ebos, J.M.L. (2018). A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal. Cell Rep 25, 3706-3720 e3708.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

### 10.1016/j.celrep.2018.12.017.

8. Mastri, M., and Ebos, J.M.L. (2019). Tumor growth fueled by spurious senescence phenotypes. Mol Cell Oncol 6, 1575707. 10.1080/23723556.2019.1575707.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

9. Sharpless, N.E., and Sherr, C.J. (2015). Forging a signature of in vivo senescence. Nat Rev Cancer 15, 397-408. 10.1038/nrc3960.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10. Ewald, J.A., Desotelle, J.A., Wilding, G., and Jarrard, D.F. (2010). Therapy-induced senescence in cancer. J Natl Cancer Inst 102, 1536-1546. 10.1093/jnci/djq364.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)
## Parsed Citations

1. Upadhaya, S., Neftelinov, S.T., Hodge, J., and Campbell, J. (2022). Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nat Rev Drug Discov. 10.1038/d41573-022-00030-4.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

2. Vafaei, S., Zekiy, A.O., Khanamir, R.A., Zaman, B.A., Ghayourvahdat, A., Azimizonuzi, H., and Zamani, M. (2022). Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int 22, 2. 10.1186/s12935-021-02407-8.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

3. Varayathu, H., Sarathy, V., Thomas, B.E., Mufti, S.S., and Naik, R. (2021). Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. Front Oncol 11, 559161. 10.3389/fonc.2021.559161.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

4. Kohli, J., Wang, B., Brandenburg, S.M., Basisty, N., Evangelou, K., Varela-Eirin, M., Campisi, J., Schilling, B., Gorgoulis, V., and Demaria, M. (2021). Algorithmic assessment of cellular senescence in experimental and clinical specimens. Nat Protoc 16, 2471-2498. 10.1038/s41596-021-00505-5.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

5. Gonzalez-Gualda, E., Baker, A.G., Fruk, L., and Munoz-Espin, D. (2021). A guide to assessing cellular senescence in vitro and in vivo. FEBS J 288, 56-80. 10.1111/febs.15570.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

6. Davan-Wetton, C.S.A., Pessolano, E., Perretti, M., and Montero-Melendez, T. (2021). Senescence under appraisal: hopes and challenges revisited. Cell Mol Life Sci 78, 3333-3354.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

### 10.1007/s00018-020-03746-x.

7. Mastri, M., Tracz, A., Lee, C.R., Dolan, M., Attwood, K., Christensen, J.G., Liu, S., and Ebos, J.M.L. (2018). A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal. Cell Rep 25, 3706-3720 e3708.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

### 10.1016/j.celrep.2018.12.017.

8. Mastri, M., and Ebos, J.M.L. (2019). Tumor growth fueled by spurious senescence phenotypes. Mol Cell Oncol 6, 1575707. 10.1080/23723556.2019.1575707.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

9. Sharpless, N.E., and Sherr, C.J. (2015). Forging a signature of in vivo senescence. Nat Rev Cancer 15, 397-408. 10.1038/nrc3960.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10. Ewald, J.A., Desotelle, J.A., Wilding, G., and Jarrard, D.F. (2010). Therapy-induced senescence in cancer. J Natl Cancer Inst 102, 1536-1546. 10.1093/jnci/djq364.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)
11. Coppe, J.P., Desprez, P.Y., Krtolica, A., and Campisi, J. (2010). The senescence-associated secretory phenotype: the dark side of tumor suppression. Annual review of pathology 5, 99-118.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1146/annurev-pathol-121808-102144.

12. Ruscetti, M., Morris, J.P.t., Mezzadra, R., Russell, J., Leibold, J., Romesser, P.B., Simon, J., Kulick, A., Ho, Y.J., Fennell, M., et al. (2020). Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell 181, 424-441 e421.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1016/j.cell.2020.03.008.

13. Ruscetti, M., Leibold, J., Bott, M.J., Fennell, M., Kulick, A., Salgado, N.R., Chen, C.C., Ho, Y.J., Sanchez-Rivera, F.J., Feucht, J., et al. (2018). NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362, 1416-1422. 10.1126/science.aas9090.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

14. Tonnessen-Murray, C.A., Frey, W.D., Rao, S.G., Shahbandi, A., Ungerleider, N.A., Olayiwola, J.O., Murray, L.B., Vinson, B.T., Chrisey, D.B., Lord, C.J., and Jackson, J.G. (2019). Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival. J Cell Biol 218, 3827-3844.

10.1083/jcb.201904051.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

15. Duy, C., Li, M., Teater, M., Meydan, C., Garrett-Bakelman, F.E., Lee, T.C., Chin, C.R., Durmaz, C., Kawabata, K.C., Dhimolea, E., et al. (2021). Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. Cancer Discov 11, 1542-1561.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1158/2159-8290.CD-20-1375.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

16. Choi, Y.W., Kim, Y.H., Oh, S.Y., Suh, K.W., Kim, Y.S., Lee, G.Y., Yoon, J.E., Park, S.S., Lee, Y.K., Park, Y.J., et al. (2021). Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer. Adv Sci (Weinh) 8, 2002497. 10.1002/advs.202002497.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

17. Iannello, A., Thompson, T.W., Ardolino, M., Lowe, S.W., and Raulet, D.H. (2013). p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 210, 2057-2069. 10.1084/jem.20130783.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

18. Ovadya, Y., Landsberger, T., Leins, H., Vadai, E., Gal, H., Biran, A., Yosef, R., Sagiv, A., Agrawal, A., Shapira, A., et al. (2018). Impaired immune surveillance accelerates accumulation of senescent cells and aging. Nat Commun 9, 5435. 10.1038/s41467-018-07825-3.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

19. Cerboni, C., Fionda, C., Soriani, A., Zingoni, A., Doria, M., Cippitelli, M., and Santoni, A. (2014). The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells. Front Immunol 4, 508.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)
11. Coppe, J.P., Desprez, P.Y., Krtolica, A., and Campisi, J. (2010). The senescence-associated secretory phenotype: the dark side of tumor suppression. Annual review of pathology 5, 99-118.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1146/annurev-pathol-121808-102144.

12. Ruscetti, M., Morris, J.P.t., Mezzadra, R., Russell, J., Leibold, J., Romesser, P.B., Simon, J., Kulick, A., Ho, Y.J., Fennell, M., et al. (2020). Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell 181, 424-441 e421.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1016/j.cell.2020.03.008.

13. Ruscetti, M., Leibold, J., Bott, M.J., Fennell, M., Kulick, A., Salgado, N.R., Chen, C.C., Ho, Y.J., Sanchez-Rivera, F.J., Feucht, J., et al. (2018). NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362, 1416-1422. 10.1126/science.aas9090.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

14. Tonnessen-Murray, C.A., Frey, W.D., Rao, S.G., Shahbandi, A., Ungerleider, N.A., Olayiwola, J.O., Murray, L.B., Vinson, B.T., Chrisey, D.B., Lord, C.J., and Jackson, J.G. (2019). Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival. J Cell Biol 218, 3827-3844.

10.1083/jcb.201904051.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

15. Duy, C., Li, M., Teater, M., Meydan, C., Garrett-Bakelman, F.E., Lee, T.C., Chin, C.R., Durmaz, C., Kawabata, K.C., Dhimolea, E., et al. (2021). Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. Cancer Discov 11, 1542-1561.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1158/2159-8290.CD-20-1375.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

16. Choi, Y.W., Kim, Y.H., Oh, S.Y., Suh, K.W., Kim, Y.S., Lee, G.Y., Yoon, J.E., Park, S.S., Lee, Y.K., Park, Y.J., et al. (2021). Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer. Adv Sci (Weinh) 8, 2002497. 10.1002/advs.202002497.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

17. Iannello, A., Thompson, T.W., Ardolino, M., Lowe, S.W., and Raulet, D.H. (2013). p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 210, 2057-2069. 10.1084/jem.20130783.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

18. Ovadya, Y., Landsberger, T., Leins, H., Vadai, E., Gal, H., Biran, A., Yosef, R., Sagiv, A., Agrawal, A., Shapira, A., et al. (2018). Impaired immune surveillance accelerates accumulation of senescent cells and aging. Nat Commun 9, 5435. 10.1038/s41467-018-07825-3.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

19. Cerboni, C., Fionda, C., Soriani, A., Zingoni, A., Doria, M., Cippitelli, M., and Santoni, A. (2014). The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells. Front Immunol 4, 508.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)
10.3389/fimmu.2013.00508.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

20. Krizhanovsky, V., Yon, M., Dickins, R.A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., and Lowe, S.W. (2008). Senescence of activated stellate cells limits liver fibrosis. *Cell* 134, 657-667.

10.1016/j.cell.2008.06.049.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

21. Egashira, M., Hirota, Y., Shimizu-Hirota, R., Saito-Fujita, T., Haraguchi, H., Matsumoto, L., Matsuo, M., Hiraoka, T., Tanaka, T., Akaeda, S., et al. (2017). F4/80+ Macrophages Contribute to Clearance of Senescent Cells in the Mouse Postpartum Uterus. *Endocrinology* 158, 2344-2353.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1210/en.2016-1886.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

22. Irvine, K.M., Skoien, R., Bokil, N.J., Melino, M., Thomas, G.P., Loo, D., Gabrielli, B., Hill, M.M., Sweet, M.J., Clouston, A.D., and Powell, E.E. (2014). Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration. *World J Gastroenterol* 20, 17851-17862.

10.3748/wjg.v20.i47.17851.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

23. Xue, W., Zender, L., Miething, C., Dickins, R.A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., and Lowe, S.W. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature* 445, 656-660. 10.1038/nature05529.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

24. Pereira, B.I., Devine, O.P., Vukmanovic-Stejic, M., Chambers, E.S., Subramanian, P., Patel, N., Virasami, A., Sebire, N.J., Kinsler, V., Valdovinos, A., et al. (2019). Senescent cells evade immune clearance via HLA-E-mediated NK and CD8(+) T cell inhibition. *Nat Commun* 10, 2387. 10.1038/s41467-019-10335-5.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

25. Ruhland, M.K., Loza, A.J., Capietto, A.H., Luo, X., Knolhoff, B.L., Flanagan, K.C., Belt, B.A., Alspach, E., Leahy, K., Luo, J., et al. (2016). Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. *Nat Commun* 7, 11762.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1038/ncomms11762.

26. Garcia-Diaz, A., Shin, D.S., Moreno, B.H., Saco, J., Escuin-Ordinas, H., Rodriguez, G.A., Zaretsky, J.M., Sun, L., Hugo, W., Wang, X., et al. (2017). Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. *Cell reports* 19, 1189-1201.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1016/j.celrep.2017.04.031.

27. Yu, Q., Katlinskaya, Y.V., Carbone, C.J., Zhao, B., Katlinski, K.V., Zheng, H., Guha, M., Li, N., Chen, Q., Yang, T., et al. (2015). DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function. *Cell Rep* 11, 785-797. 10.1016/j.celrep.2015.03.069.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)
10.3389/fimmu.2013.00508.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

20. Krizhanovsky, V., Yon, M., Dickins, R.A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., and Lowe, S.W. (2008). Senescence of activated stellate cells limits liver fibrosis. *Cell* 134, 657-667.

10.1016/j.cell.2008.06.049.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

21. Egashira, M., Hirota, Y., Shimizu-Hirota, R., Saito-Fujita, T., Haraguchi, H., Matsumoto, L., Matsuo, M., Hiraoka, T., Tanaka, T., Akaeda, S., et al. (2017). F4/80+ Macrophages Contribute to Clearance of Senescent Cells in the Mouse Postpartum Uterus. *Endocrinology* 158, 2344-2353.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1210/en.2016-1886.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

22. Irvine, K.M., Skoien, R., Bokil, N.J., Melino, M., Thomas, G.P., Loo, D., Gabrielli, B., Hill, M.M., Sweet, M.J., Clouston, A.D., and Powell, E.E. (2014). Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration. *World J Gastroenterol* 20, 17851-17862.

10.3748/wjg.v20.i47.17851.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

23. Xue, W., Zender, L., Miething, C., Dickins, R.A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., and Lowe, S.W. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature* 445, 656-660. 10.1038/nature05529.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

24. Pereira, B.I., Devine, O.P., Vukmanovic-Stejic, M., Chambers, E.S., Subramanian, P., Patel, N., Virasami, A., Sebire, N.J., Kinsler, V., Valdovinos, A., et al. (2019). Senescent cells evade immune clearance via HLA-E-mediated NK and CD8(+) T cell inhibition. *Nat Commun* 10, 2387. 10.1038/s41467-019-10335-5.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

25. Ruhland, M.K., Loza, A.J., Capietto, A.H., Luo, X., Knolhoff, B.L., Flanagan, K.C., Belt, B.A., Alspach, E., Leahy, K., Luo, J., et al. (2016). Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. *Nat Commun* 7, 11762.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1038/ncomms11762.

26. Garcia-Diaz, A., Shin, D.S., Moreno, B.H., Saco, J., Escuin-Ordinas, H., Rodriguez, G.A., Zaretsky, J.M., Sun, L., Hugo, W., Wang, X., et al. (2017). Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. *Cell reports* 19, 1189-1201.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1016/j.celrep.2017.04.031.

27. Yu, Q., Katlinskaya, Y.V., Carbone, C.J., Zhao, B., Katlinski, K.V., Zheng, H., Guha, M., Li, N., Chen, Q., Yang, T., et al. (2015). DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function. *Cell Rep* 11, 785-797. 10.1016/j.celrep.2015.03.069.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)
28. Frisch, S.M., and MacFawn, I.P. (2020). Type I interferons and related pathways in cell senescence. Aging Cell 19, e13234. 10.1111/acel.13234.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

29. Takahashi, A., Loo, T.M., Okada, R., Kamachi, F., Watanabe, Y., Wakita, M., Watanabe, S., Kawamoto, S., Miyata, K., Barber, G.N., et al. (2018). Downregulation of cytoplasmic DNAs is implicated in cytoplasmic DNA accumulation and SASP in senescent cells. Nat Commun 9, 1249. 10.1038/s41467-018-03555-8.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

30. Dunphy, G., Flannery, S.M., Almine, J.F., Connolly, D.J., Paulus, C., Jonsson, K.L., Jakobsen, M.R., Nevels, M.M., Bowie, A.G., and Unterholzner, L. (2018). Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-kappaB Signaling after Nuclear DNA Damage. Mol Cell 71, 745-760 e745. 10.1016/j.molcel.2018.07.034.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

31. Yang, H., Wang, H., Ren, J., Chen, Q., and Chen, Z.J. (2017). cGAS is essential for cellular senescence. Proc Natl Acad Sci U S A 114, E4612-E4620. 10.1073/pnas.1705499114.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

32. Falahat, R., Perez-Villarroel, P., Mailloux, A.W., Zhu, G., Pilon-Thomas, S., Barber, G.N., and Mule, J.J. (2019). STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity. Cancer immunology research 7, 1837-1848. 10.1158/2326-6066.CIR-19-0229.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

33. Brenner, E., Schorg, B.F., Ahmetlic, F., Wieder, T., Hilke, F.J., Simon, N., Schroeder, C., Demidov, G., Riedel, T., Fehrenbacher, B., et al. (2020). Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun 11, 1335. 10.1038/s41467-020-14987-6.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

34. Abe, T., and Barber, G.N. (2014). Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. J Virol 88, 5328-5341. 10.1128/JVI.00037-14.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

35. Woo, S.R., Fuertes, M.B., Corrales, L., Spranger, S., Furdyna, M.J., Leung, M.Y., Duggan, R., Wang, Y., Barber, G.N., Fitzgerald, K.A., et al. (2014). STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830-842.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1016/j.immuni.2014.10.017.

36. Ishikawa, H., and Barber, G.N. (2008). STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674-678. 10.1038/nature07317.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

37. Georgilis, A., and Gil, J. (2016). Controlling secretion to limit chemoresistance. Genes Dev 30, 1791-1792. 10.1101/gad.288571.116.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)
28. Frisch, S.M., and MacFawn, I.P. (2020). Type I interferons and related pathways in cell senescence. Aging Cell 19, e13234. 10.1111/acel.13234.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

29. Takahashi, A., Loo, T.M., Okada, R., Kamachi, F., Watanabe, Y., Wakita, M., Watanabe, S., Kawamoto, S., Miyata, K., Barber, G.N., et al. (2018). Downregulation of cytoplasmic DNases is implicated in cytoplasmic DNA accumulation and SASP in senescent cells. Nat Commun 9, 1249. 10.1038/s41467-018-03555-8.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

30. Dunphy, G., Flannery, S.M., Almine, J.F., Connolly, D.J., Paulus, C., Jonsson, K.L., Jakobsen, M.R., Nevels, M.M., Bowie, A.G., and Unterholzner, L. (2018). Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-kappaB Signaling after Nuclear DNA Damage. Mol Cell 71, 745-760 e745. 10.1016/j.molcel.2018.07.034.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

31. Yang, H., Wang, H., Ren, J., Chen, Q., and Chen, Z.J. (2017). cGAS is essential for cellular senescence. Proc Natl Acad Sci U S A 114, E4612-E4620. 10.1073/pnas.1705499114.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

32. Falahat, R., Perez-Villarroel, P., Mailloux, A.W., Zhu, G., Pilon-Thomas, S., Barber, G.N., and Mule, J.J. (2019). STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity. Cancer immunology research 7, 1837-1848. 10.1158/2326-6066.CIR-19-0229.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

33. Brenner, E., Schorg, B.F., Ahmetlic, F., Wieder, T., Hilke, F.J., Simon, N., Schroeder, C., Demidov, G., Riedel, T., Fehrenbacher, B., et al. (2020). Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun 11, 1335. 10.1038/s41467-020-14987-6.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

34. Abe, T., and Barber, G.N. (2014). Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1. J Virol 88, 5328-5341. 10.1128/JVI.00037-14.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

35. Woo, S.R., Fuertes, M.B., Corrales, L., Spranger, S., Furdyna, M.J., Leung, M.Y., Duggan, R., Wang, Y., Barber, G.N., Fitzgerald, K.A., et al. (2014). STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830-842.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1016/j.immuni.2014.10.017.

36. Ishikawa, H., and Barber, G.N. (2008). STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674-678. 10.1038/nature07317.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

37. Georgilis, A., and Gil, J. (2016). Controlling secretion to limit chemoresistance. Genes Dev 30, 1791-1792. 10.1101/gad.288571.116.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)
38. Velarde, M.C., and Demaria, M. (2016). Targeting Senescent Cells: Possible Implications for Delaying Skin Aging: A Mini-Review. Gerontology 62, 513-518. 10.1159/000444877.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

39. Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., and Kirkland, J.L. (2013). Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 123, 966-972.
10.1172/JCI64098.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

40. de Keizer, P.L. (2017). The Fountain of Youth by Targeting Senescent Cells? Trends Mol Med 23, 6-17.
10.1016/j.molmed.2016.11.006.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

41. Juers, D.H., Matthews, B.W., and Huber, R.E. (2012). LacZ beta-galactosidase: structure and function of an enzyme of historical and molecular biological importance. Protein Sci 21, 1792-1807.
10.1002/pro.2165.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

42. Debacq-Chainiaux, F., Erusalimsky, J.D., Campisi, J., and Toussaint, O. (2009). Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 4, 1798-1806. 10.1038/nprot.2009.191.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

43. Morelli, M.B., Amantini, C., Santoni, M., Soriani, A., Nabissi, M., Cardinali, C., Santoni, A., and Santoni, G. (2015). Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget 6, 36245-36259.
10.18632/oncotarget.5768.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

44. Coppe, J.P., Patil, C.K., Rodier, F., Sun, Y., Munoz, D.P., Goldstein, J., Nelson, P.S., Desprez, P.Y., and Campisi, J. (2008). Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6, 2853-2868.
10.1371/journal.pbio.0060301.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

45. Rodier, F., Coppe, J.P., Patil, C.K., Hoeijmakers, W.A., Munoz, D.P., Raza, S.R., Freund, A., Campeau, E., Davalos, A.R., and Campisi, J. (2009). Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11, 973-979.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1038/ncb1909.

46. Bent, E.H., Gilbert, L.A., and Hemann, M.T. (2016). A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Genes Dev 30, 1811-1821. 10.1101/gad.284851.116.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

47. Kuilman, T., Michaloglou, C., Vredeveld, L.C., Douma, S., van Doorn, R., Desmet, C.J., Aarden, L.A., Mooi, W.J., and Peeper, D.S. (2008). Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019-1031. 10.1016/j.cell.2008.03.039.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)
38. Velarde, M.C., and Demaria, M. (2016). Targeting Senescent Cells: Possible Implications for Delaying Skin Aging: A Mini-Review. Gerontology 62, 513-518. 10.1159/000444877.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

39. Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., and Kirkland, J.L. (2013). Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 123, 966-972.

10.1172/JCI64098.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

40. de Keizer, P.L. (2017). The Fountain of Youth by Targeting Senescent Cells? Trends Mol Med 23, 6-17.

10.1016/j.molmed.2016.11.006.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

41. Juers, D.H., Matthews, B.W., and Huber, R.E. (2012). LacZ beta-galactosidase: structure and function of an enzyme of historical and molecular biological importance. Protein Sci 21, 1792-1807.

10.1002/pro.2165.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

42. Debacq-Chainiaux, F., Erusalimsky, J.D., Campisi, J., and Toussaint, O. (2009). Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 4, 1798-1806. 10.1038/nprot.2009.191.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

43. Morelli, M.B., Amantini, C., Santoni, M., Soriani, A., Nabissi, M., Cardinali, C., Santoni, A., and Santoni, G. (2015). Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget 6, 36245-36259.

10.18632/oncotarget.5768.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

44. Coppe, J.P., Patil, C.K., Rodier, F., Sun, Y., Munoz, D.P., Goldstein, J., Nelson, P.S., Desprez, P.Y., and Campisi, J. (2008). Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6, 2853-2868.

10.1371/journal.pbio.0060301.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

45. Rodier, F., Coppe, J.P., Patil, C.K., Hoeijmakers, W.A., Munoz, D.P., Raza, S.R., Freund, A., Campeau, E., Davalos, A.R., and Campisi, J. (2009). Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11, 973-979.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1038/ncb1909.

46. Bent, E.H., Gilbert, L.A., and Hemann, M.T. (2016). A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Genes Dev 30, 1811-1821. 10.1101/gad.284851.116.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

47. Kuilman, T., Michaloglou, C., Vredeveld, L.C., Douma, S., van Doorn, R., Desmet, C.J., Aarden, L.A., Mooi, W.J., and Peeper, D.S. (2008). Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019-1031. 10.1016/j.cell.2008.03.039.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)
48. Obenauf, A.C., Zou, Y., Ji, A.L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M.C., Wiesner, T., Rosen, N., et al. (2015). Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520, 368-372. 10.1038/nature14336.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/2690680)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

49. Pribluda, A., Elyada, E., Wiener, Z., Hamza, H., Goldstein, R.E., Biton, M., Burstain, I., Morgenstern, Y., Brachya, G., Billauer, H., et al. (2013). A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer cell 24, 242-256.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/2496199)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1016/j.ccr.2013.06.005.

50. Kuilman, T., and Peeper, D.S. (2009). Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 9, 81-94. 10.1038/nrc2560.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1901119)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

51. Acosta, J.C., O'Loghlen, A., Banito, A., Guijarro, M.V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008). Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-1018. 10.1016/j.cell.2008.03.038.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1869361)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

52. Rusinova, I., Forster, S., Yu, S., Kannan, A., Masse, M., Cumming, H., Chapman, R., and Hertzog, P.J. (2013). Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res 41, D1040-1046. 10.1093/nar/gks1215.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/2390876)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

53. Grullich, C. (2018). Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. Recent Results Cancer Res 211, 67-75. 10.1007/978-3-319-91442-8_5.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/2918191)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

54. Wood, C.G., Ferguson, J.E., 3rd, Parker, J.S., Moore, D.T., Whisenant, J.G., Maygarden, S.J., Wallen, E.M., Kim, W.Y., Milowsky, M.I., Beckermann, K.E., et al. (2020). Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight 5.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1504150)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1172/jci.insight.132852.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/2899377)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

55. Braga, S., Cardoso, J., Andre, S., Brito, M., Sanchez, P., Orvalho, L., Salgado, L., Dias, S., Pereira-Leal, J.B., and Passos-Coelho, J.L. (2017). Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer? Curr Cancer Drug Targets 17, 62-73. 10.2174/1568009616666161025114914.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/2899377)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

56. Diaz-Montero, C.M., Mao, F.J., Barnard, J., Parker, Y., Zamanian-Daryoush, M., Pink, J.J., Finke, J.H., Rini, B.I., and Lindner, D.J. (2016). MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Br J Cancer 115, 920-928.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/2899377)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1038/bjc.2016.263.
48. Obenauf, A.C., Zou, Y., Ji, A.L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M.C., Wiesner, T., Rosen, N., et al. (2015). Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520, 368-372. 10.1038/nature14336.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/nlm/authorTitle)

Google Scholar: [Google Scholar Search](https://scholar.google.com/search?q=Author+and+Title)

49. Pribluda, A., Elyada, E., Wiener, Z., Hamza, H., Goldstein, R.E., Biton, M., Burstain, I., Morgenstern, Y., Brachya, G., Billauer, H., et al. (2013). A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer cell 24, 242-256.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/nlm/authorTitle)

Google Scholar: [Google Scholar Search](https://scholar.google.com/search?q=Author+and+Title)

10.1016/j.ccr.2013.06.005.

50. Kuilman, T., and Peeper, D.S. (2009). Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 9, 81-94. 10.1038/nrc2560.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/nlm/authorTitle)

Google Scholar: [Google Scholar Search](https://scholar.google.com/search?q=Author+and+Title)

51. Acosta, J.C., O'Loghlen, A., Banito, A., Guijarro, M.V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008). Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-1018. 10.1016/j.cell.2008.03.038.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/nlm/authorTitle)

Google Scholar: [Google Scholar Search](https://scholar.google.com/search?q=Author+and+Title)

52. Rusinova, I., Forster, S., Yu, S., Kannan, A., Masse, M., Cumming, H., Chapman, R., and Hertzog, P.J. (2013). Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res 41, D1040-1046. 10.1093/nar/gks1215.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/nlm/authorTitle)

Google Scholar: [Google Scholar Search](https://scholar.google.com/search?q=Author+and+Title)

53. Grullich, C. (2018). Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. Recent Results Cancer Res 211, 67-75. 10.1007/978-3-319-91442-8_5.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/nlm/authorTitle)

Google Scholar: [Google Scholar Search](https://scholar.google.com/search?q=Author+and+Title)

54. Wood, C.G., Ferguson, J.E., 3rd, Parker, J.S., Moore, D.T., Whisenant, J.G., Maygarden, S.J., Wallen, E.M., Kim, W.Y., Milowsky, M.I., Beckermann, K.E., et al. (2020). Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight 5.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/nlm/authorTitle)

Google Scholar: [Google Scholar Search](https://scholar.google.com/search?q=Author+and+Title)

10.1172/jci.insight.132852.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/nlm/authorTitle)

Google Scholar: [Google Scholar Search](https://scholar.google.com/search?q=Author+and+Title)

55. Braga, S., Cardoso, J., Andre, S., Brito, M., Sanchez, P., Orvalho, L., Salgado, L., Dias, S., Pereira-Leal, J.B., and Passos-Coelho, J.L. (2017). Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer? Curr Cancer Drug Targets 17, 62-73. 10.2174/1568009616666161025114914.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/nlm/authorTitle)

Google Scholar: [Google Scholar Search](https://scholar.google.com/search?q=Author+and+Title)

56. Diaz-Montero, C.M., Mao, F.J., Barnard, J., Parker, Y., Zamanian-Daryoush, M., Pink, J.J., Finke, J.H., Rini, B.I., and Lindner, D.J. (2016). MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Br J Cancer 115, 920-928.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/nlm/authorTitle)

Google Scholar: [Google Scholar Search](https://scholar.google.com/search?q=Author+and+Title)

10.1038/bjc.2016.263.
57. Pan, B.S., Perera, S.A., Piesvaux, J.A., Presland, J.P., Schroeder, G.K., Cumming, J.N., Trotter, B.W., Altman, M.D., Buevich, A.V., Cash, B., et al. (2020). An orally available non-nucleotide STING agonist with antitumor activity. *Science* 369. 10.1126/science.aba6098.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

58. Prantner, D., Perkins, D.J., Lai, W., Williams, M.S., Sharma, S., Fitzgerald, K.A., and Vogel, S.N. (2012). 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. *J Biol Chem* 287, 39776-39788. 10.1074/jbc.M112.382986.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

59. Conlon, J., Burdette, D.L., Sharma, S., Bhat, N., Thompson, M., Jiang, Z., Rathinam, V.A., Monks, B., Jin, T., Xiao, T.S., et al. (2013). Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. *J Immunol* 190, 5216-5225.
10.4049/jimmunol.1300097.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

60. Braumuller, H., Wieder, T., Brenner, E., Assmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013). T-helper-1-cell cytokines drive cancer into senescence. *Nature* 494, 361-365. 10.1038/nature11824.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

61. De Cecco, M., Ito, T., Petrashen, A.P., Elias, A.E., Skvir, N.J., Criscione, S.W., Caligiana, A., Brocculi, G., Adney, E.M., Boeke, J.D., et al. (2019). L1 drives IFN in senescent cells and promotes age-associated inflammation. *Nature* 566, 73-78. 10.1038/s41586-018-0784-9.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

62. Trinchieri, G. (2010). Type I interferon: friend or foe? *J Exp Med* 207, 2053-2063.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1084/jem.20101664.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

63. Fenton, S.E., Saleiro, D., and Platanias, L.C. (2021). Type I and II Interferons in the Anti-Tumor Immune Response. *Cancers* (Basel) 13. 10.3390/cancers13051037.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

64. Marin, I., Boix, O., Garcia-Garijo, A., Sirois, I., Caballe, A., Zarzuela, E., Ruano, I., Attolini, C.S., Prats, N., Lopez-Dominguez, J.A., et al. (2023). Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity. *Cancer discovery* 13, 410-431. 10.1158/2159-8290.CD-22-0523.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

65. Vaghi, C., Rodallec, A., Fanciullino, R., Ciccolini, J., Mochel, J.P., Mastri, M., Poignard, C., Ebos, J.M.L., and Benzekry, S. (2020). Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. *PLoS Comput Biol* 16, e1007178.
10.1371/journal.pcbi.1007178.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

66. Quah, B.J., and Parish, C.R. (2010). The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation. *J Vis Exp.* 10.3791/2259.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)
57. Pan, B.S., Perera, S.A., Piesvaux, J.A., Presland, J.P., Schroeder, G.K., Cumming, J.N., Trotter, B.W., Altman, M.D., Buevich, A.V., Cash, B., et al. (2020). An orally available non-nucleotide STING agonist with antitumor activity. *Science* 369. 10.1126/science.aba6098.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

58. Prantner, D., Perkins, D.J., Lai, W., Williams, M.S., Sharma, S., Fitzgerald, K.A., and Vogel, S.N. (2012). 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. *J Biol Chem* 287, 39776-39788. 10.1074/jbc.M112.382986.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

59. Conlon, J., Burdette, D.L., Sharma, S., Bhat, N., Thompson, M., Jiang, Z., Rathinam, V.A., Monks, B., Jin, T., Xiao, T.S., et al. (2013). Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. *J Immunol* 190, 5216-5225.
10.4049/jimmunol.1300097.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

60. Braumuller, H., Wieder, T., Brenner, E., Assmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013). T-helper-1-cell cytokines drive cancer into senescence. *Nature* 494, 361-365. 10.1038/nature11824.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

61. De Cecco, M., Ito, T., Petrashen, A.P., Elias, A.E., Skvir, N.J., Criscione, S.W., Caligiana, A., Brocculi, G., Adney, E.M., Boeke, J.D., et al. (2019). L1 drives IFN in senescent cells and promotes age-associated inflammation. *Nature* 566, 73-78. 10.1038/s41586-018-0784-9.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

62. Trinchieri, G. (2010). Type I interferon: friend or foe? *J Exp Med* 207, 2053-2063.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1084/jem.20101664.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

63. Fenton, S.E., Saleiro, D., and Platanias, L.C. (2021). Type I and II Interferons in the Anti-Tumor Immune Response. *Cancers* (Basel) 13. 10.3390/cancers13051037.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

64. Marin, I., Boix, O., Garcia-Garijo, A., Sirois, I., Caballe, A., Zarzuela, E., Ruano, I., Attolini, C.S., Prats, N., Lopez-Dominguez, J.A., et al. (2023). Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity. *Cancer discovery* 13, 410-431. 10.1158/2159-8290.CD-22-0523.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

65. Vaghi, C., Rodallec, A., Fanciullino, R., Ciccolini, J., Mochel, J.P., Mastri, M., Poignard, C., Ebos, J.M.L., and Benzekry, S. (2020). Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. *PLoS Comput Biol* 16, e1007178.
10.1371/journal.pcbi.1007178.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

66. Quah, B.J., and Parish, C.R. (2010). The use of carboxyfluorescein diacetate succinimidyl ester (CFSE) to monitor lymphocyte proliferation. *J Vis Exp.* 10.3791/2259.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)
67. Medema, J.P., de Jong, J., Peltenburg, L.T., Verdegaal, E.M., Gorter, A., Bres, S.A., Franken, K.L., Hahne, M., Albar, J.P., Melief, C.J., and Offringa, R. (2001). Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 98, 11515-11520.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3837607)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1073/pnas.201398198.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3837607)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

68. Mosely, S.I., Prime, J.E., Sainson, R.C., Koopmann, J.O., Wang, D.Y., Greenawalt, D.M., Ahdesmaki, M.J., Leyland, R., Mullins, S., Pacelli, L., et al. (2017). Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer immunology research 5, 29-41. 10.1158/2326-6066.CIR-16-0114.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3837607)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

69. Mall, C., Sckisel, G.D., Proia, D.A., Mirsoian, A., Grossenbacher, S.K., Pai, C.S., Chen, M., Monjazeb, A.M., Kelly, K., Blazar, B.R., and Murphy, W.J. (2016). Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology 5, e1075114.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3837607)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1080/2162402X.2015.1075114.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3837607)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

70. Monjazeb, A.M., Wang, Z., Vick, L.V., Dunai, C., Minnar, C., Khuat, L.T., and Murphy, W.J. (2021). Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms. Cancers (Basel) 13.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3837607)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.3390/cancers13040729.

71. Motzer, R.J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M.T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019). Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380, 1103-1115.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3837607)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1056/NEJMoa1816047.

72. Rini, B.I., Plimack, E.R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019). Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380, 1116-1127. 10.1056/NEJMoa1816714.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3837607)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

73. Motzer, R.J., Robbins, P.B., Powles, T., Albiges, L., Haanen, J.B., Larkin, J., Mu, X.J., Ching, K.A., Uemura, M., Pal, S.K., et al. (2020). Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3837607)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1038/s41591-020-1044-8.

74. Choueiri, T.K., Powles, T., Burotto, M., Escudier, B., Bourlon, M.T., Zurawski, B., Oyervides Juarez, V.M., Hsieh, J.J., Basso, U., Shah, A.Y., et al. (2021). Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 384, 829-841.
67. Medema, J.P., de Jong, J., Peltenburg, L.T., Verdegaal, E.M., Gorter, A., Bres, S.A., Franken, K.L., Hahne, M., Albar, J.P., Melief, C.J., and Offringa, R. (2001). Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 98, 11515-11520.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3812109)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1073/pnas.201398198.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3812109)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

68. Mosely, S.I., Prime, J.E., Sainson, R.C., Koopmann, J.O., Wang, D.Y., Greenawalt, D.M., Ahdesmaki, M.J., Leyland, R., Mullins, S., Pacelli, L., et al. (2017). Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer immunology research 5, 29-41. 10.1158/2326-6066.CIR-16-0114.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3812109)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

69. Mall, C., Sckisel, G.D., Proia, D.A., Mirsoian, A., Grossenbacher, S.K., Pai, C.S., Chen, M., Monjazeb, A.M., Kelly, K., Blazar, B.R., and Murphy, W.J. (2016). Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology 5, e1075114.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3812109)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1080/2162402X.2015.1075114.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3812109)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

70. Monjazeb, A.M., Wang, Z., Vick, L.V., Dunai, C., Minnar, C., Khuat, L.T., and Murphy, W.J. (2021). Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms. Cancers (Basel) 13.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3812109)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.3390/cancers13040729.

71. Motzer, R.J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M.T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019). Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380, 1103-1115.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3812109)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1056/NEJMoa1816047.

72. Rini, B.I., Plimack, E.R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019). Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380, 1116-1127. 10.1056/NEJMoa1816714.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3812109)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

73. Motzer, R.J., Robbins, P.B., Powles, T., Albiges, L., Haanen, J.B., Larkin, J., Mu, X.J., Ching, K.A., Uemura, M., Pal, S.K., et al. (2020). Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pmc/abstract/3812109)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1038/s41591-020-1044-8.

74. Choueiri, T.K., Powles, T., Burotto, M., Escudier, B., Bourlon, M.T., Zurawski, B., Oyervides Juarez, V.M., Hsieh, J.J., Basso, U., Shah, A.Y., et al. (2021). Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 384, 829-841.
## 10.1056/NEJMoa2026982.

75. Heine, A., Held, S.A., Bringmann, A., Holderried, T.A., and Brossart, P. (2011). Immunomodulatory effects of anti-angiogenic drugs. Leukemia 25, 899-905.

## 10.1038/leu.2011.24.

76. Stehle, F., Schulz, K., Fahldieck, C., Kalich, J., Lichtenfels, R., Riemann, D., and Seliger, B. (2013). Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem 288, 16334-16347. 10.1074/jbc.M112.437962.

77. Prasanna, P.G., Citrin, D.E., Hildesheim, J., Ahmed, M.M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., Deursen, J.V., Goronzy, J., et al. (2021). Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. J Natl Cancer Inst 113, 1285-1298.

## 10.1093/jnci/djab064.

78. Wang, L., Lankhorst, L., and Bernards, R. (2022). Exploiting senescence for the treatment of cancer. Nat Rev Cancer 22, 340-355. 10.1038/s41568-022-00450-9.

79. Zhang, L., Pitcher, L.E., Prahalad, V., Niedernhofer, L.J., and Robbins, P.D. (2023). Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J 290, 1362-1383.

## 10.1111/febs.16350.

80. Wang, B., and Demaria, M. (2021). The Quest to Define and Target Cellular Senescence in Cancer. Cancer Res 81, 6087-6089. 10.1158/0008-5472.CAN-21-2032.

81. Lee, S., and Schmitt, C.A. (2019). The dynamic nature of senescence in cancer. Nat Cell Biol 21, 94-101. 10.1038/s41556-018-0249-2.

82. Chakradeo, S., Elmore, L.W., and Gewirtz, D.A. (2016). Is Senescence Reversible? Curr Drug Targets 17, 460-466.

83. Romaniello, D., Gelfo, V., Pagano, F., Ferlizza, E., Sgarzi, M., Mazzeschi, M., Morselli, A., Miano, C., D'Uva, G., and Lauriola, M. (2022). Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization. Cell Mol Biol Lett 27, 20.

## 10.1186/s11658-022-00319-7.
## 10.1056/NEJMoa2026982.

75. Heine, A., Held, S.A., Bringmann, A., Holderried, T.A., and Brossart, P. (2011). Immunomodulatory effects of anti-angiogenic drugs. Leukemia 25, 899-905.

## 10.1038/leu.2011.24.

76. Stehle, F., Schulz, K., Fahldieck, C., Kalich, J., Lichtenfels, R., Riemann, D., and Seliger, B. (2013). Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem 288, 16334-16347. 10.1074/jbc.M112.437962.

77. Prasanna, P.G., Citrin, D.E., Hildesheim, J., Ahmed, M.M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., Deursen, J.V., Goronzy, J., et al. (2021). Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. J Natl Cancer Inst 113, 1285-1298.

## 10.1093/jnci/djab064.

78. Wang, L., Lankhorst, L., and Bernards, R. (2022). Exploiting senescence for the treatment of cancer. Nat Rev Cancer 22, 340-355. 10.1038/s41568-022-00450-9.

79. Zhang, L., Pitcher, L.E., Prahalad, V., Niedernhofer, L.J., and Robbins, P.D. (2023). Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J 290, 1362-1383.

## 10.1111/febs.16350.

80. Wang, B., and Demaria, M. (2021). The Quest to Define and Target Cellular Senescence in Cancer. Cancer Res 81, 6087-6089. 10.1158/0008-5472.CAN-21-2032.

81. Lee, S., and Schmitt, C.A. (2019). The dynamic nature of senescence in cancer. Nat Cell Biol 21, 94-101. 10.1038/s41556-018-0249-2.

82. Chakradeo, S., Elmore, L.W., and Gewirtz, D.A. (2016). Is Senescence Reversible? Curr Drug Targets 17, 460-466.

83. Romaniello, D., Gelfo, V., Pagano, F., Ferlizza, E., Sgarzi, M., Mazzeschi, M., Morselli, A., Miano, C., D'Uva, G., and Lauriola, M. (2022). Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization. Cell Mol Biol Lett 27, 20.

## 10.1186/s11658-022-00319-7.
84. Salunkhe, S., Mishra, S.V., Nair, J., Shah, S., Gardi, N., Thorat, R., Sarkar, D., Rajendra, J., Kaur, E., and Dutt, S. (2021). Nuclear localization of p65 reverses therapy-induced senescence. J Cell Sci 134. 10.1242/jcs.253203.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

85. Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C.B., Roberto, M.P., Tovar, V., Sia, D., Molina-Sanchez, P., Nguyen, C.B., et al. (2017). Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut 66, 1286-1296. 10.1136/gutjnl-2016-312268.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

86. Maskey, R.S., Wang, F., Lehman, E., Wang, Y., Emmanuel, N., Zhong, W., Jin, G., Abraham, R.T., Arndt, K.T., Myers, J.S., and Mazurek, A. (2021). Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells. Cell Cycle 20, 65-80. 10.1080/15384101.2020.1859195.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

87. Fleury, H., Malaquin, N., Tu, V., Gilbert, S., Martinez, A., Olivier, M.A., Sauriol, A., Communal, L., Leclerc-Desaulniers, K., Carmona, E., et al. (2019). Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat Commun 10, 2556. 10.1038/s41467-019-10460-1.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

88. Madorsky Rowdo, F.P., Baron, A., von Euw, E.M., and Mordoh, J. (2017). In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. Oncol Rep 37, 1367-1378. 10.3892/or.2017.5363.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

89. Kurppa, K.J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E.H., Xie, Y., Lim, K., Cejas, P., et al. (2020). Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell 37, 104-122 e112.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

10.1016/j.ccell.2019.12.006.

90. Hu, Z., Yuan, J., Long, M., Jiang, J., Zhang, Y., Zhang, T., Xu, M., Fan, Y., Tanyi, J.L., Montone, K.T., et al. (2021). The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer 2, 1406-1422. 10.1038/s43018-021-00282-w.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

91. Saleh, T., Tyutyunyk-Massey, L., Murray, G.F., Alotaibi, M.R., Kawale, A.S., Elsayed, Z., Henderson, S.C., Yakovlev, V., Elmore, L.W., Toor, A., et al. (2019). Tumor cell escape from therapy-induced senescence. Biochem Pharmacol 162, 202-212. 10.1016/j.bcp.2018.12.013.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

92. Hao, X., Zhao, B., Zhou, W., Liu, H., Fukumoto, T., Gabrilovich, D., and Zhang, R. (2021). Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. iScience 24, 102016. 10.1016/j.isci.2020.102016.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

93. Paffenholz, S.V., Salvagno, C., Ho, Y.J., Limjoco, M., Baslan, T., Tian, S., Kulick, A., de Stanchina, E., Wilkinson, J.E., Barriga, F.M., et al. (2022). Senescence induction dictates response to chemo- and
84. Salunkhe, S., Mishra, S.V., Nair, J., Shah, S., Gardi, N., Thorat, R., Sarkar, D., Rajendra, J., Kaur, E., and Dutt, S. (2021). Nuclear localization of p65 reverses therapy-induced senescence. J Cell Sci 134. 10.1242/jcs.253203.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

85. Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C.B., Roberto, M.P., Tovar, V., Sia, D., Molina-Sanchez, P., Nguyen, C.B., et al. (2017). Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut 66, 1286-1296. 10.1136/gutjnl-2016-312268.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

86. Maskey, R.S., Wang, F., Lehman, E., Wang, Y., Emmanuel, N., Zhong, W., Jin, G., Abraham, R.T., Arndt, K.T., Myers, J.S., and Mazurek, A. (2021). Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells. Cell Cycle 20, 65-80. 10.1080/15384101.2020.1859195.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

87. Fleury, H., Malaquin, N., Tu, V., Gilbert, S., Martinez, A., Olivier, M.A., Sauriol, A., Communal, L., Leclerc-Desaulniers, K., Carmona, E., et al. (2019). Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat Commun 10, 2556. 10.1038/s41467-019-10460-1.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

88. Madorsky Rowdo, F.P., Baron, A., von Euw, E.M., and Mordoh, J. (2017). In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. Oncol Rep 37, 1367-1378. 10.3892/or.2017.5363.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

89. Kurppa, K.J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E.H., Xie, Y., Lim, K., Cejas, P., et al. (2020). Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell 37, 104-122 e112.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

## 10.1016/j.ccell.2019.12.006.

90. Hu, Z., Yuan, J., Long, M., Jiang, J., Zhang, Y., Zhang, T., Xu, M., Fan, Y., Tanyi, J.L., Montone, K.T., et al. (2021). The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer 2, 1406-1422. 10.1038/s43018-021-00282-w.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

91. Saleh, T., Tyutyunyk-Massey, L., Murray, G.F., Alotaibi, M.R., Kawale, A.S., Elsayed, Z., Henderson, S.C., Yakovlev, V., Elmore, L.W., Toor, A., et al. (2019). Tumor cell escape from therapy-induced senescence. Biochem Pharmacol 162, 202-212. 10.1016/j.bcp.2018.12.013.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

92. Hao, X., Zhao, B., Zhou, W., Liu, H., Fukumoto, T., Gabrilovich, D., and Zhang, R. (2021). Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. iScience 24, 102016. 10.1016/j.isci.2020.102016.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

93. Paffenholz, S.V., Salvagno, C., Ho, Y.J., Limjoco, M., Baslan, T., Tian, S., Kulick, A., de Stanchina, E., Wilkinson, J.E., Barriga, F.M., et al. (2022). Senescence induction dictates response to chemo- and
immunotherapy in preclinical models of ovarian cancer. Proc Natl Acad Sci U S A 119.

10.1073/pnas.2117754119.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

94. Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A.K., Kothari, A., Wang, D., Visal, T., Li, M.K., Pinto, J., Castrillon, J.A., et al. (2019). PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov 9, 722-737. 10.1158/2159-8290.CD-18-1218.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

95. Jing, W., McAllister, D., Vonderhaar, E.P., Palen, K., Riese, M.J., Gershan, J., Johnson, B.D., and Dwinell, M.B. (2019). STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. J Immunother Cancer 7, 115.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1186/s40425-019-0573-5.

96. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., Vitale, I., Goubar, A., Baracco, E.E., Remedios, C., et al. (2014). Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20, 1301-1309. 10.1038/nm.3708.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

97. Adachi, Y., Kamiyama, H., Ichikawa, K., Fukushima, S., Ozawa, Y., Yamaguchi, S., Goda, S., Kimura, T., Kodama, K., Matsuki, M., et al. (2022). Inhibition of FGFR Reactivates IFNgamma Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. Cancer Res 82, 292-306. 10.1158/0008-5472.CAN-20-2426.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

98. Goel, S., DeCristo, M.J., Watt, A.C., BrinJones, H., Sceneay, J., Li, B.B., Khan, N., Ubellacker, J.M., Xie, S., Metzger-Filho, O., et al. (2017). CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471-475. 10.1038/nature23465.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

99. Yang, H., Lee, W.S., Kong, S.J., Kim, C.G., Kim, J.H., Chang, S.K., Kim, S., Kim, G., Chon, H.J., and Kim, C. (2019). STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest 129, 4350-4364. 10.1172/JCI125413.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

100. Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., and et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92, 9363-9367.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1073/pnas.92.20.9363.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

101. Kurz, D.J., Decary, S., Hong, Y., and Erusalimsky, J.D. (2000). Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 113 (Pt 20), 3613-3622. 10.1242/jcs.113.20.3613.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/)

Google Scholar: [Google Scholar Search](https://scholar.google.com)
immunotherapy in preclinical models of ovarian cancer. Proc Natl Acad Sci U S A 119.
10.1073/pnas.2117754119.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

94. Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A.K., Kothari, A., Wang, D., Visal, T., Li, M.K., Pinto, J., Castrillon, J.A., et al. (2019). PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. Cancer Discov 9, 722-737. 10.1158/2159-8290.CD-18-1218.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

95. Jing, W., McAllister, D., Vonderhaar, E.P., Palen, K., Riese, M.J., Gershan, J., Johnson, B.D., and Dwinell, M.B. (2019). STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. J Immunother Cancer 7, 115.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1186/s40425-019-0573-5.

96. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., Vitale, I., Goubar, A., Baracco, E.E., Remedios, C., et al. (2014). Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20, 1301-1309. 10.1038/nm.3708.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

97. Adachi, Y., Kamiyama, H., Ichikawa, K., Fukushima, S., Ozawa, Y., Yamaguchi, S., Goda, S., Kimura, T., Kodama, K., Matsuki, M., et al. (2022). Inhibition of FGFR Reactivates IFNgamma Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies. Cancer Res 82, 292-306. 10.1158/0008-5472.CAN-20-2426.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

98. Goel, S., DeCristo, M.J., Watt, A.C., BrinJones, H., Sceneay, J., Li, B.B., Khan, N., Ubellacker, J.M., Xie, S., Metzger-Filho, O., et al. (2017). CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471-475. 10.1038/nature23465.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

99. Yang, H., Lee, W.S., Kong, S.J., Kim, C.G., Kim, J.H., Chang, S.K., Kim, S., Kim, G., Chon, H.J., and Kim, C. (2019). STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J Clin Invest 129, 4350-4364. 10.1172/JCI125413.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

100. Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., Pereira-Smith, O., and et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92, 9363-9367.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1073/pnas.92.20.9363.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

101. Kurz, D.J., Decary, S., Hong, Y., and Erusalimsky, J.D. (2000). Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 113 (Pt 20), 3613-3622. 10.1242/jcs.113.20.3613.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)
102. Lee, B.Y., Han, J.A., Im, J.S., Morrone, A., Johung, K., Goodwin, E.C., Kleijer, W.J., DiMaio, D., and Hwang, E.S. (2006). Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 5, 187-195. 10.1111/j.1474-9726.2006.00199.x.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

103. Ruzickova, E., Skoupa, N., Dolezel, P., Smith, D.A., and Mlejnek, P. (2019). The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance. Biomolecules 9.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.3390/biom9110675.

104. Gotink, K.J., Broxterman, H.J., Labots, M., de Haas, R.R., Dekker, H., Honeywell, R.J., Rudek, M.A., Beerepoot, L.V., Musters, R.J., Jansen, G., et al. (2011). Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17, 7337-7346. 10.1158/1078-0432.CCR-11-1667.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

105. Fassl, A., Brain, C., Abu-Remaileh, M., Stukan, I., Butter, D., Stepien, P., Feit, A.S., Bergholz, J., Michowski, W., Otto, T., et al. (2020). Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Sci Adv 6, eabb2210.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1126/sciadv.abb2210.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

106. Colombo, F., Trombetta, E., Cetrangolo, P., Maggioni, M., Razini, P., De Santis, F., Torrente, Y., Prati, D., Torresani, E., and Porretti, L. (2014). Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells. PLoS One 9, e114787.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1371/journal.pone.0114787.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

107. Zhang, H., Zoued, A., Liu, X., Sit, B., and Waldor, M.K. (2020). Type I interferon remodels lysosome function and modifies intestinal epithelial defense. Proc Natl Acad Sci U S A 117, 29862-29871.

10.1073/pnas.2010723117.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

108. Unterholzner, L., and Dunphy, G. (2019). cGAS-independent STING activation in response to DNA damage. Mol Cell Oncol 6, 1558682. 10.1080/23723556.2018.1558682.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

109. Elgendy, M., Abdel-Aziz, A.K., Renne, S.L., Bornaghi, V., Procopio, G., Colecchia, M., Kanesvaran, R., Toh, C.K., Bossi, D., Pallavicini, I., et al. (2017). Dual modulation of MCL-1 and mTOR determines the response to sunitinib. J Clin Invest 127, 153-168. 10.1172/JCI84386.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

110. Jimenez-Valerio, G., Martinez-Lozano, M., Bassani, N., Vidal, A., Ochoa-de-Olza, M., Suarez, C., Garcia-Del-Muro, X., Carles, J., Vinals, F., Graupera, M., et al. (2016). Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Cell Rep 15, 1134-1143. 10.1016/j.celrep.2016.04.015.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)
102. Lee, B.Y., Han, J.A., Im, J.S., Morrone, A., Johung, K., Goodwin, E.C., Kleijer, W.J., DiMaio, D., and Hwang, E.S. (2006). Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 5, 187-195. 10.1111/j.1474-9726.2006.00199.x.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

103. Ruzickova, E., Skoupa, N., Dolezel, P., Smith, D.A., and Mlejnek, P. (2019). The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance. Biomolecules 9.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.3390/biom9110675.

104. Gotink, K.J., Broxterman, H.J., Labots, M., de Haas, R.R., Dekker, H., Honeywell, R.J., Rudek, M.A., Beerepoot, L.V., Musters, R.J., Jansen, G., et al. (2011). Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17, 7337-7346. 10.1158/1078-0432.CCR-11-1667.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

105. Fassl, A., Brain, C., Abu-Remaileh, M., Stukan, I., Butter, D., Stepien, P., Feit, A.S., Bergholz, J., Michowski, W., Otto, T., et al. (2020). Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Sci Adv 6, eabb2210.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1126/sciadv.abb2210.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

106. Colombo, F., Trombetta, E., Cetrangolo, P., Maggioni, M., Razini, P., De Santis, F., Torrente, Y., Prati, D., Torresani, E., and Porretti, L. (2014). Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells. PLoS One 9, e114787.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

10.1371/journal.pone.0114787.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

107. Zhang, H., Zoued, A., Liu, X., Sit, B., and Waldor, M.K. (2020). Type I interferon remodels lysosome function and modifies intestinal epithelial defense. Proc Natl Acad Sci U S A 117, 29862-29871.

10.1073/pnas.2010723117.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

108. Unterholzner, L., and Dunphy, G. (2019). cGAS-independent STING activation in response to DNA damage. Mol Cell Oncol 6, 1558682. 10.1080/23723556.2018.1558682.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

109. Elgendy, M., Abdel-Aziz, A.K., Renne, S.L., Bornaghi, V., Procopio, G., Colecchia, M., Kanesvaran, R., Toh, C.K., Bossi, D., Pallavicini, I., et al. (2017). Dual modulation of MCL-1 and mTOR determines the response to sunitinib. J Clin Invest 127, 153-168. 10.1172/JCI84386.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)

110. Jimenez-Valerio, G., Martinez-Lozano, M., Bassani, N., Vidal, A., Ochoa-de-Olza, M., Suarez, C., Garcia-Del-Muro, X., Carles, J., Vinals, F., Graupera, M., et al. (2016). Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Cell Rep 15, 1134-1143. 10.1016/j.celrep.2016.04.015.

Pubmed: [Author and Title](https://www.ncbi.nlm.nih.gov/pubmed/1234567890)

Google Scholar: [Google Scholar Search](https://scholar.google.com)
111. Zhang, L., Wei, X., Wang, Z., Liu, P., Hou, Y., Xu, Y., Su, H., Koci, M.D., Yin, H., and Zhang, C. (2023). NF-kappaB activation enhances STING signaling by altering microtubule-mediated STING trafficking. Cell Rep 42, 112185. 10.1016/j.celrep.2023.112185.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

112. Benci, J.L., Xu, B., Qiu, Y., Wu, T.J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D.S.M., Pauken, K.E., Huang, A.C., et al. (2016). Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell 167, 1540-1554 e1512.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

## 10.1016/j.cell.2016.11.022.

113. Shi, Y., Dolan, M., Mastri, M., Hill, J.W., Dommer, A., Benzekry, S., Eng, K., and Ebos, J.M.L. (2021). Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells. bioRxiv, 2021.2007.2001.450417.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

## 10.1101/2021.07.01.450417.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

114. Jacquelot, N., Yamazaki, T., Roberti, M.P., Duong, C.P.M., Andrews, M.C., Verlingue, L., Ferrere, G., Becharef, S., Vetizou, M., Daillere, R., et al. (2019). Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res 29, 846-861. 10.1038/s41422-019-0224-x.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

115. Dolan, M., Mastri, M., Tracz, A., Christensen, J.G., Chatta, G., and Ebos, J.M.L. (2019). Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. PLoS One 14, e0220101. 10.1371/journal.pone.0220101.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

116. Ebos, J.M., Mastri, M., Lee, C.R., Tracz, A., Hudson, J.M., Attwood, K., Cruz-Munoz, W.R., Jedeszko, C., Burns, P., and Kerbel, R.S. (2014). Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol Med 6, 1561-1576.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

## 10.15252/emmm.201403989.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

117. Ebos, J.M., Lee, C.R., Bogdanovic, E., Alami, J., Van Slyke, P., Francia, G., Xu, P., Mutsaers, A.J., Dumont, D.J., and Kerbel, R.S. (2008). Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 68, 521-529. 10.1158/0008-5472.CAN-07-3217.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

118. Tracz, A., Mastri, M., Lee, C.R., Pili, R., and Ebos, J.M. (2014). Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy. J Vis Exp.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

## 10.3791/51485.

119. Mundra, P.A., and Rajapakse, J.C. (2016). Gene and sample selection using T-score with sample selection. J Biomed Inform 59, 31-41. 10.1016/j.jbi.2015.11.003.
111. Zhang, L., Wei, X., Wang, Z., Liu, P., Hou, Y., Xu, Y., Su, H., Koci, M.D., Yin, H., and Zhang, C. (2023). NF-kappaB activation enhances STING signaling by altering microtubule-mediated STING trafficking. Cell Rep 42, 112185. 10.1016/j.celrep.2023.112185.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

112. Benci, J.L., Xu, B., Qiu, Y., Wu, T.J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D.S.M., Pauken, K.E., Huang, A.C., et al. (2016). Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell 167, 1540-1554 e1512.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

## 10.1016/j.cell.2016.11.022.

113. Shi, Y., Dolan, M., Mastri, M., Hill, J.W., Dommer, A., Benzekry, S., Eng, K., and Ebos, J.M.L. (2021). Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells. bioRxiv, 2021.2007.2001.450417.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

## 10.1101/2021.07.01.450417.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

114. Jacquelot, N., Yamazaki, T., Roberti, M.P., Duong, C.P.M., Andrews, M.C., Verlingue, L., Ferrere, G., Becharef, S., Vetizou, M., Daillere, R., et al. (2019). Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res 29, 846-861. 10.1038/s41422-019-0224-x.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

115. Dolan, M., Mastri, M., Tracz, A., Christensen, J.G., Chatta, G., and Ebos, J.M.L. (2019). Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance. PLoS One 14, e0220101. 10.1371/journal.pone.0220101.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

116. Ebos, J.M., Mastri, M., Lee, C.R., Tracz, A., Hudson, J.M., Attwood, K., Cruz-Munoz, W.R., Jedeszko, C., Burns, P., and Kerbel, R.S. (2014). Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol Med 6, 1561-1576.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

## 10.15252/emmm.201403989.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

117. Ebos, J.M., Lee, C.R., Bogdanovic, E., Alami, J., Van Slyke, P., Francia, G., Xu, P., Mutsaers, A.J., Dumont, D.J., and Kerbel, R.S. (2008). Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 68, 521-529. 10.1158/0008-5472.CAN-07-3217.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

118. Tracz, A., Mastri, M., Lee, C.R., Pili, R., and Ebos, J.M. (2014). Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy. J Vis Exp.

Pubmed: [Author and Title](#)

Google Scholar: [Google Scholar Search](#)

## 10.3791/51485.

119. Mundra, P.A., and Rajapakse, J.C. (2016). Gene and sample selection using T-score with sample selection. J Biomed Inform 59, 31-41. 10.1016/j.jbi.2015.11.003.